New drug cuts relapse risk by half in rare immune disorder trial

Stanford Medicine researchers and their colleagues found that a new drug, obexelimab, significantly reduces the risk of relapse in patients with IgG4-related disease, a rare chronic immune condition often misdiagnosed as cancer.